NOT KNOWN FACTUAL STATEMENTS ABOUT BLOCK PAIN RECEPTORS WITH PROLEVIATE

Owning recognized the palmitoylation motif of APLNR, we designed a brief substrate sequence to competitively inhibit the palmitoylation of endogenous APLNR. This competitive peptide, which targets the APLNR palmitoylation web-site in combination with morphine, can inhibit the development of NCP, which include pain incidence, microglial activation,